Acellular lung matrix scaffold coated by fibronectin enhances hepatic differentiation of adipose-derived mesenchymal stem cells.
Nejad DB., Azandeh SS., Bayati V., Orazizadeh M., Baazm M., Younesi E.
Laboratory Study, published in Anat Cell Biol (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Anat Cell Biol (2026)
- Country
- Korea (South)
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 42547247
- DOI
- 10.5115/acb.26.061
Abstract (original English)
End-stage liver disease is a multifactorial disorder and leading cause of death. The development of effective tissue models has been a focus of research for treating liver disease. This study investigated the use of acellular lung matrix (ALM) and fibronectin (FN) to culture adipose-derived mesenchymal stem cells (ADMSCs) and promote their differentiation into hepatic-like cells. In this experimental study, sodium deoxycholate and NaCl were used to decellularize the lungs, and scaffolds were characterized by histology, scanning electron microscopy, and DNA quantification. ADMSCs were differentiated into hepatocyte-like cells using a two-step protocol under three conditions: in two-dimensional culture, on ALM scaffolds, and on FN-coated ALM scaffolds. Hepatic differentiation was confirmed by RT-PCR for specific genes (alpha-fetoprotein [AFP], albumin [ALB], cytokeratin-18 [CK-18]), ALB and urea levels were measured using specific commercial kits. The main extracellular matrix components (collagen and glycosaminoglycans) were preserved, and residual DNA was minimal ( P <0.001), indicating effective decellularization. ADMSCs cultured on FN-coated ALM exhibited significantly higher expression of hepatic markers (AFP, P <0.01; ALB, P <0.01; CK-18, P <0.01). Functional assay confirmed higher ALB and urea production ( P <0.05), while MTT assay demonstrated that the scaffold was non-cy
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.